Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting

Pharmaceutical Research

Volumn 31, Issue 11, 2014, Pages 2988-3005

  Song, Shuangshuang ^a   Qi, Huan ^a   Xu, Jingwen ^a   Guo, Pan ^a   Chen, Fen ^a   Li, Fei ^a   Yang, Xinggang ^a   Sheng, Naicheng ^b   Wu, Yingliang ^a   Pan, Weisan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b INSTITUTE OF METAL RESEARCH   (China)

Author keywords

CD44 mediated endocytosis; hyaluronan; interference with endogenous HA CD44 interaction; tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG CARRIER; HERMES ANTIGEN; HYALURONIC ACID; NANOPARTICLE; TAXOID;

ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; FEMALE; GENETICS; HUMAN; MALE; MCF 7 CELL LINE; MOUSE; PARTICLE SIZE; RAT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HUMANS; HYALURONIC ACID; MALE; MCF-7 CELLS; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS;

EID: 84932121396     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1393-4     Document Type: Article

References (52)

1. Du C, Deng D, Shan L, Wan S, Cao J, Tian J, et al. A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery. Biomaterials. 2013;34:3087-97.
2. Huo M, Zou A, Yao C, Zhang Y, Zhou J, Wang J, et al. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials. 2012;33:6393-407.
3. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine: NBM. 2010;6:714-29.
4. Shen M, Huang Y, Han L, Qin J, Fang X, Wang J, et al. Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. J Control Release. 2012;161:884-92.
5. Cui Y, Xu Q, Chow PK-H, Wang D, Wang C-H. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials. 2013;34:8511-20.
6. Wang M, Hu H, Sun Y, Qiu L, Zhang J, Guan G, et al. A pH-sensitive gene delivery system based on folic acid-PEG-chitosan-PAMAM-plasmid DNA complexes for cancer cell targeting. Biomaterials. 2013;34:10120-32.
7. Zhang B, Sun X, Mei H, Wang Y, Liao Z, Chen J, et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34:9171-82.
8. Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C, et al. Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. J Control Release. 2013;172:201-6.
9. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces. 2010;75:1-18.
10. Li Y, Wang J, Wientjes MG, Au JLS. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev. 2012;64:29-39.
11. Prakash S, Malhotra M, Shao W, Tomaro-Duchesneau C, Abbasi S. Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Adv Drug Deliv Rev. 2011;63:1340-51.
12. Leeand JY, Spicer AP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol. 2000;12:581-6.
13. Robert L, Robert AM, Renard G. Biological effects of hyaluronan in connective tissues, eye, skin, venous wall. Role in aging. Pathol Biol. 2010;58:187-98.
14. Bullard KM, Kim H-R, Wheeler MA, Wilson CM, Neudauer CL, Simpson MA, et al. Hyaluronan synthase-3 is upregulated in metastatic colon carcinoma cells and manipulation of expression alters matrix retention and cellular growth. Int J Cancer. 2003;107:739-46.
15. Itano N, Sawai T, Yoshida M, Lenas P, Yamada Y, Imagawa M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem. 1999;274:25085-92.
16. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33-45.
17. Sternand R, Jedrzejas MJ. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev. 2006;106:818-39.
18. Stern R. Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol. 2004;83:317-25.
19. Bourguignon LYW. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol. 2008;18:251-9.
20. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528-39.
21. Bourguignon LYW, Wong G, Earle C, Krueger K, Spevak CC. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, MicroRNA-10b expression, and RhoA/RhoC up-regulation, leading to rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010;285:36721-35.
22. Götteand M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006;66:10233-7.
23. Kim H-R, Wheeler MA, Wilson CM, Iida J, Eng D, Simpson MA, et al. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res. 2004;64:4569-76.
24. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med. 1994;180:53-66.
25. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem. 2002;277:38013-20.
26. Yoshihara S, Kon A, Kudo D, Nakazawa H, Kakizaki I, Sasaki M, et al. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett. 2005;579:2722-6.
27. Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer. 1998;77:396-401.
28. Heldin C-H, Rubin K, Pietras K, Östman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806-13.
29. Zahalka MA, Okon E, Gosslar U, Holzmann B, Naor D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44-and hyaluronate-dependent. J Immunol. 1995;154:5345-55.
30. Luo Y, Bernshaw NJ, Lu Z-R, Kopecek J, Prestwich GD. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm Res. 2002;19:396-402.
31. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules. 2000;1:208-18.
32. Ganesh S, Iyer AK, Morrissey DV, Amiji MM. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials. 2013;34:3489-502.
33. Kumar A, Sahoo B, Montpetit A, Behera S, Lockey RF, Mohapatra SS. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine: NBM. 2007;3:132-7.
34. Lee H, Mok H, Lee S, Oh Y-K, Park TG. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release. 2007;119:245-52.
35. Yoon HY, Koo H, Choi KY, Lee SJ, Kim K, Kwon IC, et al. Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials. 2012;33:3980-9.
36. Laroui H, Grossin L, Léonard M, Stoltz J-F, Gillet P, Netter P, et al. Hyaluronate-covered nanoparticles for the therapeutic targeting of cartilage. Biomacromolecules. 2007;8:3879-85.
37. Surace C, Arpicco S, Dufaÿ-Wojcicki AL, Marsaud VR, Bouclier CL, Clay D, et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Mol Pharm. 2009;6:1062-73.
38. Song S, Chen F, Qi H, Li F, Xin T, Xu J et al. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel. Pharm Res 2013;31:1-14.
39. Yu J-M, Li Y-J, Qiu L-Y, Jin Y. Self-aggregated nanoparticles of cholesterol-modified glycol chitosan conjugate: preparation, characterization, and preliminary assessment as a new drug delivery carrier. Eur Polym J. 2008;44:555-65.
40. Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C, et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(γ-benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials. 2010;31:2882-92.
41. Liu Y, Sun J, Cao W, Yang J, Lian H, Li X, et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm. 2011;421:160-9.
42. Itano N. Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. J Biochem. 2008;144:131-7.
43. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol. 2006;85:699-715.
44. Chao KL, Muthukumar L, Herzberg O. Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis. Biochemistry. 2007;46:6911-20.
45. Choi KY, Yoon HY, Kim J-H, Bae SM, Park R-W, Kang YM, et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano. 2011;5:8591-9.
46. Fraser J, Laurent T, Laurent U. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997;242:27-33.
47. Laurentand TC, Fraser J. Hyaluronan. FASEB J. 1992;6:2397-404.
48. Chen H, Kim S, He W, Wang H, Low PS, Park K, et al. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir. 2008;24:5213-7.
49. Almalik A, Karimi S, Ouasti S, Donno R, Wandrey C, Day PJ, et al. Hyaluronic acid (HA) presentation as a tool to modulate and control the receptor-mediated uptake of HA-coated nanoparticles. Biomaterials. 2013;34:5369-80.
50. Gaucher G, Asahina K, Wang J, Leroux J-C. Effect of poly (N-vinyl-pyrrolidone)-block-poly (D, L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules. 2009;10:408-16.
51. Aguiar DJ, Knudson W, Knudson CB. Internalization of the hyaluronan receptor CD44 by chondrocytes. Exp Cell Res. 1999;252:292-302.
52. Ouasti S, Kingham PJ, Terenghi G, Tirelli N. The CD44/integrins interplay and the significance of receptor binding and re-presentation in the uptake of RGD-functionalized hyaluronic acid. Biomaterials. 2012;33:1120-34.